> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# DEA Rewrites 7-OH Thresholds as Emergency Scheduling Advances
- URL: https://www.theamericanquorum.com/dea-rewrites-7-oh-thresholds-emergency-scheduling/
- Published: 2026-10-09T21:39:07.000Z
- Updated: 2026-10-09T21:39:07.000Z
- Description: The Justice Department will restart emergency scheduling for concentrated 7-OH and MGPI using new concentration and ratio tests. Related synthetic opioids remain controlled, while 7-OH itself is not yet federally scheduled.
- Author: News Desk
- Tags: Policy

The Justice Department is restarting part of its emergency drug-scheduling process for concentrated 7-hydroxymitragynine products after federal health officials revised the scientific thresholds meant to separate trace botanical content from deliberately enhanced opioids. The change keeps two related synthetic compounds under Schedule I controls, preserves temporary controls on a third while a new notice is pending, and confirms that 7-OH itself has not yet been temporarily scheduled at the federal level.

Under the [Oct. 9 action](https://www.justice.gov/opa/pr/department-justice-announces-updates-emergency-scheduling-actions-7-oh-and-related-opioid?ref=theamericanquorum.com), the Drug Enforcement Administration will issue two new notices of intent. One will reissue the approach for MGM-15 and MGM-16 without changing their current status. The other will apply revised concentration and ratio tests to 7-OH and mitragynine pseudoindoxyl, or MGPI. DEA temporarily placed MGPI, MGM-15 and MGM-16 in Schedule I on Aug. 26; those controls remain in effect during the new 30-day notice period and until a replacement temporary order is issued.

The legal status of 7-OH is different. DEA announced an intended temporary schedule in July but never published the final temporary order. It will now issue a replacement notice based on the updated Health and Human Services analysis. That means the new federal threshold is a proposal within an emergency process, not an already-effective nationwide ban on every product containing 7-OH.

## How the new threshold works

HHS now [recommends](https://www.hhs.gov/press-room/hhs-recommends-thresholds-enhanced-kratom-products-7-oh-mgpi.html?ref=theamericanquorum.com) Schedule I control when 7-OH, MGPI or their combined amount exceeds 1 milligram per gram in a solid product or 1 milligram per milliliter in a liquid. A product would also meet the threshold when the ratio of mitragynine to 7-OH, MGPI or their combined amount is less than 100 to 1\. The ratio test is intended to identify formulations in which the opioid compounds are elevated relative to mitragynine, the principal alkaloid associated with botanical kratom.

The revision reflects updated science about trace constituents. HHS said 7-OH occurs naturally at low levels in botanical kratom and that developing evidence suggests MGPI may also appear in trace amounts in some botanical or kratom-derived products. Applying concentration and ratio tests to both compounds is meant to distinguish naturally occurring chemistry from products that have been intentionally enhanced or concentrated.

That is a meaningful change from DEA’s July [notice](https://www.federalregister.gov/documents/2026/07/06/2026-13580/schedules-of-controlled-substance-temporary-placement-of-7-hydroxymitragynine-above-a-specified?ref=theamericanquorum.com). The earlier proposal generally covered botanical material above 0.050 percent 7-OH by dry weight and certain extracts or finished products above 0.050 percent or 1 milligram per article. It did not use the new 100-to-1 ratio. HHS sought public input on whether another concentration or measurement method would better identify an imminent public-safety hazard, and the replacement notice incorporates the agency’s resulting recommendation.

## What Schedule I would change

Temporary scheduling is an expedited authority under the Controlled Substances Act. DEA may place a substance in Schedule I for two years, with a possible one-year extension while permanent scheduling proceeds, if the agency finds that control is necessary to avoid an imminent hazard to public safety. Schedule I brings federal criminal, civil and administrative controls to manufacture, distribution, import, export, research and possession. The [category](https://www.dea.gov/drug-information/drug-scheduling?ref=theamericanquorum.com) is reserved for substances deemed to have high abuse potential, no currently accepted medical use and no accepted safety for use under medical supervision.

The July record said concentrated 7-OH has opioid activity and that commercial products were appearing as tablets, gummies, powders and dissolvable films with unclear doses. It also said no controlled human trials had established safe consumption limits or standardized dosing for those concentrated products. The Food and Drug Administration separately [recommended](https://www.fda.gov/news-events/press-announcements/fda-takes-steps-restrict-7-oh-opioid-products-threatening-american-consumers?ref=theamericanquorum.com) federal scheduling in July 2025 while emphasizing that its focus was concentrated 7-OH rather than traditional leaf material.

For MGPI, MGM-15 and MGM-16, federal control is already in place. The Justice Department’s Aug. 25 [announcement](https://www.justice.gov/opa/pr/justice-department-announces-emergency-scheduling-three-potent-opioid-compounds?ref=theamericanquorum.com) described the substances as potent opioid compounds posing an imminent hazard. Friday’s update does not release them from control. It adjusts the process by acknowledging that trace MGPI may occur in some botanical material and by establishing a threshold for MGPI alongside 7-OH, while MGM-15 and MGM-16 continue under the same scheduling approach.

## A narrower line than “kratom ban”

Federal agencies have repeatedly framed the policy as targeted at enhanced products, not ordinary botanical leaf that stays below the thresholds. That distinction matters because 7-OH is both a naturally occurring minor alkaloid and a compound that can be produced or concentrated from mitragynine. [Reuters](https://www.reuters.com/legal/litigation/dea-moves-place-some-strong-kratom-related-products-under-strict-federal-drug-2026-07-01/?ref=theamericanquorum.com) reported in July that regulators were focusing on pills, gummies, powders and liquid products containing far higher amounts than occur naturally.

The federal action also does not displace stricter state laws. Some states ban kratom or specified 7-OH products; others cap concentrations, impose age limits or regulate labeling. A product that falls below the eventual federal threshold could still be unlawful under state law or violate food and drug rules. Conversely, the absence of a current federal Schedule I order for 7-OH does not mean FDA has approved the substance as a medicine, dietary supplement or food ingredient.

The next legally important document will be DEA’s new Federal Register notice. It should specify the formal threshold language, explain the supporting findings and begin a fresh 30-day period before a temporary order can issue. Until that order is published, sellers and consumers should not treat Friday’s announcement as proof that 7-OH has already entered Schedule I nationwide. The policy direction is clear—target concentrated opioid products while carving out trace botanical levels—but the effective date and enforceable text for 7-OH still depend on the next step.